Withdraw from the registration of ChiCTR Effect of dexmedetomidine on early cognitive function in patients treated with endoscopic therapy

Effect of dexmedetomidine on early cognitive function in patients treated with endoscopic therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022639

Enrollment

Unknown

Registered

2019-04-19

Start date

2019-05-01

Completion date

Unknown

Last updated

2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive function

Interventions

Group P:None

Group S1:dexmedetomidine 30min

Group S2:dexmedetomidine 60min

Group C1:propofol 30min

Group C2:propofol 60min

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Scheduled for selective painless endoscopic therapy, ASA Grade I-II, Aged 30-65 years.

Exclusion criteria

Exclusion criteria: Severe cardiovascular diseases, atrioventricular block, abnormal liver and kidney function, obesity (BMI > 25kg/m2) and dexmedetomidine allergy were excluded.

Design outcomes

Primary

Measure	Time frame
cognitive function;	—

Countries

China

Contacts

Public ContactLina Lin

The First Affiliated Hospital of Wenzhou Medical University

544649314@qq.com+86 13587688101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026